AI assistant
THERACRYF PLC Remuneration Information 2022
7964_def-14a_2022-12-14_714ed049-0501-4080-96c5-e3ee73786770.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7510J
Evgen Pharma PLC
14 December 2022
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").
| PDMR | Position | Current Ordinary Shares held | Current Options held | New options granted | % of issued share capital including this award |
| Dr Huw Jones | CEO | 62,500 | 4,648,890 | 4,410,727 | 3.3% |
| Richard Moulson | CFO | 45,454 | 889,728 | 1,460,855 | 0.9% |
The Options will vest on the third anniversary of grant based on performance against challenging
strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).
Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.
Enquiries:
| Evgen Pharma plcDr Huw Jones, CEO Richard Moulson, CFO |
+44 1625 466591 |
| FinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane/Nigel Birks (ECM) |
+44 20 7220 0500 |
| Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon |
+44 207 457 2020 [email protected] |
The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Huw Jones | |
| 2 | Reason for the notification | ||
| a) | Position/status | CEO | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Evgen Pharma Plc | |
| b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Options over Ordinary Shares of 0.25 pence each GB00BSVYN304 |
|
| b) | Nature of the transaction | Grant of options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| nil | 4410727 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
As above | |
| f) | Date of the transaction | 14 December 2022 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Richard Moulson | |
| 2 | Reason for the notification | ||
| a) | Position/status | CFO | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Evgen Pharma Plc | |
| b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Options over Ordinary Shares of 0.25 pence each GB00BSVYN304 |
|
| b) | Nature of the transaction | Grant of options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| nil | 1460855 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
As above | |
| f) | Date of the transaction | 14 December 2022 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUSRBRUSUUAAA